Kingdon Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,039,275
Closed -$4.09M – 75
2026
Q2
$4.09M Hold
1,039,275
– – 0.42% 64
2026
Q1
$3.2M Hold
1,039,275
– – 0.35% 59
2025
Q4
$1.57M Buy
+1,039,275
New +$2.47M 0.19% 66
2016
Q1
– Sell
-543
Closed -$767K – 119
2015
Q4
$767K Sell
543
-3,521
-87% -$6.13M 0.04% 112
2015
Q3
$6.81M Sell
4,064
-510
-11% -$1.05M 0.33% 72
2015
Q2
$9.9M Buy
4,574
+389
+9% +$753K 0.39% 78
2015
Q1
$7.66M Buy
4,185
+679
+19% +$1.5M 0.33% 85
2014
Q4
$8.37M Buy
3,506
+2,241
+177% +$5.32M 0.36% 79
2014
Q3
$3.1M Buy
+1,265
New +$3.6M 0.14% 132

Other funds holding ELDN

Kingdon Capital Management's ELDN Position: Q3 2026 in Review

Kingdon Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2026, closing a stake of 1,039,275 shares — an estimated $4.09M sold.

Kingdon Capital Management first reported a position in ELDN in Q3 2014 and held it in 9 quarters. The position peaked at $9.9M in Q2 2015. 155 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • Kingdon Capital Management reported no remaining Eledon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Kingdon Capital Management sold 1,039,275 Eledon Pharmaceuticals shares in Q3 2026, an estimated $4.09M.
  • Kingdon Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 9 quarters.
  • Kingdon Capital Management's Eledon Pharmaceuticals position peaked at $9.9M in Q2 2015.
  • 155 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Kingdon Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.